journal article·2015-01-23Open access

The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy

Maryam Hosseini, Mostafa Haji-Fatahaliha, Farhad Jadidi-Niaragh, Jafar Majidi, Mehdi Yousefi

Abstract

Cancer is one of the most important causes of death all over the world, which has not yet been treated efficiently. Although several therapeutic approaches have been used, some side effects such as toxicity and drug resistance have been observed in patients, particularly with chemotherapy. The nanoparticle-mediated drug delivery systems (DDS) have a great potential to improve cancer treatment by transferring therapeutic factors directly to the tumor site. Such a treatment significantly decreases the adverse effects associated with cancer therapy on healthy tissues. Two main strategies, including passive and active methods, have been considered to be effective techniques which can target the drugs to the tumor sites. The current review sheds some light on the place of nanotechnology in cancer drug delivery, and introduces nanomaterials and their specific characteristics that can be used in tumor therapy. Moreover, passive and active targeting approaches focus on antibodies, particularly single chain variable fragments (scFv), as a novel and important ligand in a drug delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Abou-Jawde R · Clin Ther · 2003 · 25 · 212110.1016/S0149-2918(03)80209-6 ↗
2. Adams GP · Cancer Res · 2001 · 61 · 4750
3. 10.1155/2012/98025010.1155/2012/980250 ↗
4. 10.1021/nn800395t10.1021/nn800395t ↗
5. 10.1038/nrc90310.1038/nrc903 ↗
6. 10.1016/0165-6147(94)90314-X10.1016/0165-6147(94)90314-X ↗
7. Amato G · Nanoscale Res Lett · 2010 · 5 · 115610.1007/s11671-010-9619-9 ↗
8. 10.1007/s11095-008-9661-910.1007/s11095-008-9661-9 ↗
9. 10.1016/S1748-0132(07)70084-110.1016/S1748-0132(07)70084-1 ↗
10. 10.1111/j.2042-7158.2010.01167.x10.1111/j.2042-7158.2010.01167.x ↗
11. 10.1201/978142002799010.1201/9781420027990 ↗
12. 10.1038/nbt.179110.1038/nbt.1791 ↗
13. 10.1016/j.addr.2012.09.03310.1016/j.addr.2012.09.033 ↗
14. Bray F · Nat Rev Cancer · 2006 · 6 · 6310.1038/nrc1781 ↗
15. 10.1385/MB:27:1:5910.1385/MB:27:1:59 ↗
16. Cabral H · Journal of Controlled Release · 2014 · 190 · 46510.1016/j.jconrel.2014.06.042 ↗
17. 10.1016/j.addr.2005.09.01110.1016/j.addr.2005.09.011 ↗
18. 10.1038/3502522010.1038/35025220 ↗
19. 10.1038/3510107210.1038/35101072 ↗
20. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
21. 10.1016/j.tibtech.2011.03.00110.1016/j.tibtech.2011.03.001 ↗
22. 10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
23. 10.1002/ijc.291061052010.1002/ijc.2910610520 ↗
24. 10.1038/nrd261410.1038/nrd2614 ↗
25. 10.1016/j.jconrel.2006.08.01310.1016/j.jconrel.2006.08.013 ↗
26. Di Pasqua AJ · Chem Biodivers · 2009 · 6 · 134310.1002/cbdv.200900021 ↗
27. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗
28. Dou S · Adv Healthc Mater · 2014 · 3 · 179210.1002/adhm.201400037 ↗
29. Douer D · Blood · 2001 · 97 · 7310.1182/blood.V97.1.73 ↗
30. Echeverría JC · J Non-Cryst Solids · 2010 · 356 · 37810.1016/j.jnoncrysol.2009.11.044 ↗
31. 10.1021/nn900002m10.1021/nn900002m ↗
32. 10.1038/nrc156610.1038/nrc1566 ↗
33. Fidalgo A · J Sol-Gel Sci Technol · 2009 · 49 · 32010.1007/s10971-008-1880-3 ↗
34. 10.1016/j.nano.2008.04.00310.1016/j.nano.2008.04.003 ↗
35. Gaillard PJ · PloS one · 2014 · 9 · e8233110.1371/journal.pone.0082331 ↗
36. 10.1016/S1359-6446(03)02714-410.1016/S1359-6446(03)02714-4 ↗
37. 10.1023/A:101834092032910.1023/A:1018340920329 ↗
38. Guo S · Biotechnology advances · 2013
39. Hajdu SI · Cancer · 2011 · 117 · 109710.1002/cncr.25553 ↗
40. Haley B, Frenkel E. 2008. Nanoparticles for drug delivery in cancer treatment. In: Urologic Oncology: Seminars and original investigations. Elsevier: 57–64.10.1016/j.urolonc.2007.03.015 ↗
41. 10.1038/nbt114210.1038/nbt1142 ↗
42. Hu C-MJ · Therapeu Deliv · 2010 · 1 · 32310.4155/tde.10.13 ↗
43. 10.1016/S0958-1669(98)80014-110.1016/S0958-1669(98)80014-1 ↗
44. 10.3322/CA.2007.001010.3322/CA.2007.0010 ↗
45. 10.1021/es048729l10.1021/es048729l ↗
46. Kato Y · J Controlled Release · 1996 · 39 · 19110.1016/0168-3659(95)00153-0 ↗
47. 10.1038/256495a010.1038/256495a0 ↗
48. 10.1016/j.ijpharm.2010.12.03610.1016/j.ijpharm.2010.12.036 ↗
49. 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
50. Kyung OY · J Nanopart Res · 2009 · 11 · 1510.1007/s11051-008-9417-9 ↗
51. 10.1016/j.addr.2004.01.00810.1016/j.addr.2004.01.008 ↗
52. Li Z · J Colloid Interface Sci · 2010 · 342 · 60710.1016/j.jcis.2009.10.073 ↗
53. 10.1016/j.addr.2007.11.00910.1016/j.addr.2007.11.009 ↗
54. 10.1016/j.taap.2006.10.00410.1016/j.taap.2006.10.004 ↗
55. Liu X · Biomaterials · 2010 · 31 · 819810.1016/j.biomaterials.2010.07.069 ↗
56. 10.1016/j.biomaterials.2010.12.06110.1016/j.biomaterials.2010.12.061 ↗
57. Luo X · Biomaterials · 2011 · 32 · 631610.1016/j.biomaterials.2011.05.020 ↗
58. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
59. 10.1016/S1470-2045(12)70476-X10.1016/S1470-2045(12)70476-X ↗
60. Manchester M · Adv Drug Deliv Rev · 2006 · 58 · 150510.1016/j.addr.2006.09.014 ↗
61. Mansour AM · Cancer Res · 2003 · 63 · 4062
62. Marty C · Cancer Lett · 2006 · 235 · 29810.1016/j.canlet.2005.04.029 ↗
63. Mao Y · Clinical Cancer Research · 2013 · 19 · 34710.1158/1078-0432.CCR-12-2046 ↗
64. 10.1093/annonc/mdh09210.1093/annonc/mdh092 ↗
65. 10.1146/annurev.bioeng.2.1.33910.1146/annurev.bioeng.2.1.339 ↗
66. Mellet CO · Chemical Society Reviews · 2011 · 40 · 158610.1039/C0CS00019A ↗
67. Miele E · International journal of nanomedicine · 2009 · 4 · 99
68. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-610.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 ↗
69. 10.3390/antib202019310.3390/antib2020193 ↗
70. Murakami T · Nanomedicine (Lond) · 2008 · 3 · 45310.2217/17435889.3.4.453 ↗
71. Naqvi S · Int J Nanomedicine · 2010 · 5 · 98310.2147/IJN.S13244 ↗
72. 10.1021/bp049839z10.1021/bp049839z ↗
73. Nevozhay D · Postepy Hig Med Dosw (Online) · 2006 · 61 · 350
74. 10.1016/S0168-3659(97)00185-510.1016/S0168-3659(97)00185-5 ↗
75. O’Brien S · Journal of clinical oncology · 2013 · 31 · 67610.1200/JCO.2012.46.2309 ↗
76. 10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
77. 10.1016/j.toxlet.2008.10.01210.1016/j.toxlet.2008.10.012 ↗
78. 10.1002/adfm.20080165510.1002/adfm.200801655 ↗
79. 10.1038/nrc189110.1038/nrc1891 ↗
80. 10.1016/j.addr.2005.09.01410.1016/j.addr.2005.09.014 ↗
81. Pavlinkova G · Int J Cancer · 2001 · 94 · 71710.1002/ijc.1523 ↗
82. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
83. Peer D · Proc Natl Acad Sci · 2007 · 104 · 409510.1073/pnas.0608491104 ↗
84. 10.1038/sj.onc.120959710.1038/sj.onc.1209597 ↗
85. Perez E · 2005
86. Petrelli NJ · J Clin Oncol · 2009 · 27 · 605210.1200/JCO.2009.26.6171 ↗
87. Pillai G · SAGE Open Medicine · 2013 · 110.1177/2050312113513759 ↗
88. Popovici R · J Pharm Sci · 2011 · 100 · 70410.1002/jps.22308 ↗
89. Pucca MB · Braz J Pharm Sci · 2011 · 47 · 31
90. 10.1124/pr.54.4.56110.1124/pr.54.4.561 ↗
91. Riggio C · Journal of Nanomaterials · 2011 · 17
92. Rivera E · The oncologist · 2003 · 8 · 310.1634/theoncologist.8-suppl_2-3 ↗
93. 10.1158/0008-5472.CAN-04-200810.1158/0008-5472.CAN-04-2008 ↗
94. 10.1309/5CWPU41AFR1VYM3F10.1309/5CWPU41AFR1VYM3F ↗
95. Santos Giuberti CD · J Liposome Res · 2011 · 21 · 6010.3109/08982101003754377 ↗
96. Sapra P · Cancer Res · 2002 · 62 · 7190
97. Senzer NN · Molecular Cancer Therapeutics · 2009 · 8 · C3610.1158/1535-7163.TARG-09-C36 ↗
98. 10.1038/mt.2013.3210.1038/mt.2013.32 ↗
99. 10.1016/j.ijpharm.2004.12.01010.1016/j.ijpharm.2004.12.010 ↗
100. Shiba K · Nihon Rinsho · 2006 · 64 · 239